Advertisement

Clinical Aspects of Tardive Dyskinesia

Epidemiology, Natural History, and Management
  • George Gardos
  • Jonathan O. Cole

Abstract

Public awareness often seems to lag behind the appearance of a phenomenon by several years. The history of tardive dyskinesia (TD) is a good example. Although the first reports of the syndrome started to appear in the early 1960s, it was not until the late 1960s and early 1970s that the psychiatric profession became aware of the existence of the condition. As the literature began to swell with ever-increasing numbers of reports on TD during the 1970s, there was gradually increasing concern over this apparently iatrogenic condition, which has created alarm over the use of neuroleptics. The pendulum may be starting to swing back in response to recent reports which suggest that TD is not always irreversible, and that the prognosis is usually better than was at first feared. This chapter will provide an overview of the prevalence, course, prognosis, and management of TD. Because of the enormous amount of relevant research data, the literature review will be selective.

Keywords

Tardive Dyskinesia Fusaric Acid Neuroleptic Treatment Abnormal Involuntary Movement Scale Orofacial Dyskinesia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Balbessarini, R. J. (chairperson),1980 ADA Task Force on Tardive Dyskinesia, American Psychiatric Association, Washington, DC.Google Scholar
  2. Barnes, T. R. E., Kidger, T., and Gore, S. M., 1983, Tardive dyskinesia: A 3-year follow-up study, Psychol. Med. 13: 71.PubMedCrossRefGoogle Scholar
  3. Casey, D. E., 1985, Spontaneous and tardive dyskinesia: Clinical and laboratory studies, J. Clin. Psychiatry 46 (4, Sec. 2): 42–47.PubMedGoogle Scholar
  4. Casey, D. E., and Toenniessen, L. M., 1983a, Neuroleptic treatment in tardive dyskinesia: Can it be developed into a clinical strategy for long-term treatment? in: Modern Problems in Pharmacopsychiatry ( J. Bannet and R. H. Belmaker, eds), pp. 65–79, Karger, Basel.Google Scholar
  5. Casey, D. E., and Toenniessen, L. M., 1983b, Tardive dyskinesia: What is the natural history? Int. Drug. Ther. Newsl. 18 (No. 4).Google Scholar
  6. Chien, C-P., and Cole, J. O., 1973, Eighteen-months follow-up of tardive dyskinesia treated with various catecholamine-related agents, Psychopharmacol. Bull. 9: 38.Google Scholar
  7. Chouinard, G., Annable, L., Ross-Chouinard, A., and Nestoros, J. N., 1979, Factors related to tardive dyskinesia, Am. J. Psychiatry 136: 79.PubMedGoogle Scholar
  8. Crane, G. E., 1970, High doses of trifluoperazine and tardive dyskinesia, Arch. Neurol. 22:176. Crane, G. E., 1972, Pseudoparkinsonism and tardive dyskinesia, Arch. Neurol. 27: 426.CrossRefGoogle Scholar
  9. Crane, G. E., 1975, Tardive dyskinesia, A review, in: Neuropsychopharmacology ( J. R. Boissier, H. Hippius, and P. Pichot, eds.), pp. 346–354, Excerpta Medica, Elsevier, Amsterdam.Google Scholar
  10. Degkwitz, R., Consbruch, U., Haddenbrock, S., Neusch, B., Oehlert, W., and Unsold, R., 1976, Therapeutische Risiken bei der Langzeitbehandlung mit Neuroleptika und Lithium: Klinische, histologische and biochemische Befunde, Nervenarzt. 47: 81.PubMedGoogle Scholar
  11. Fann, W. E., Sullivan, J. L., and Richman, B. W., 1976, Dyskinesias associated with tricyclic antidepressants, Br. J. Psychiatry 128: 490.PubMedCrossRefGoogle Scholar
  12. Gardos, G., and Cole, J. 0., 1980, Overview: Public health issues in tardive dyskinesia, Am. J. Psychiatry 137: 776.PubMedGoogle Scholar
  13. Gardos, G., and Cole, J. 0., 1983, Tardive dyskinesia and anticholinergic drugs, Am. J. Psychiatry 140: 200.PubMedGoogle Scholar
  14. Gardos, G., Cole, J. O., Haskell, D. S., Moore, P., Bartell, Y., Salomon, M., and Schniebolk, S., 1982, A longitudinal study of early dyskinesia: Preliminary report. Proceedings of the 135th meeting of the American Psychiatric Association, Toronto 68D: 171.Google Scholar
  15. Gardos, G., Perenyi, A., Cole, J. O., Samu, I., and Kallos, M., 1983, Tardive dyskinesia: Changes after three years, J. Clin. Psychopharmacol. 3: 315.PubMedGoogle Scholar
  16. Gardos, G., Cole, J. O., Salomon, M., and Schniebolk, S., 1984, Severe tardive dyskinesia. Proceedings of the 137th meeting of the American Psychiatric Association, Los Angeles 59D: 140.Google Scholar
  17. Guy, W., 1976, Abnormal involuntary movements scale, in: ECDEU Assessment Manual for Psychopharmacoloy, pp. 534–537, US Department of HEW, Publication No. 76–338, US Government Printing Office, Washington, DC.Google Scholar
  18. Heinrich, K., Wegener, I., and Bender, H. J., 1968, Spate extrapyramidale Hyperkinesen bei neuroleptischer Langzeittherapie, Pharmacopsychiat. Neuropsychopharmacol. 1: 169.Google Scholar
  19. Jeste, D. V., and Wyatt, R. J., 1979, In search of treatment for tardive dyskinesia: Review of the literature, Schizophrenia Bull. 5: 252.Google Scholar
  20. Kane, J., Woerner, M., Weinhold, P., Wegner, J., and Kinon, B., 1982, A prospective study of tardive dyskinesia development: Preliminary results, J. Clin. Psychopharmacol. 5: 345.Google Scholar
  21. Kane, J. M., and Smith, J. M., 1982, Tardive dyskinesia: Prevalence and risk factors 1959 to 1979, Arch. Gen. Psychiatry 39: 473.PubMedCrossRefGoogle Scholar
  22. Quitkin, F., Rifkin, A., Gochfeld, L., and Klein, D. F., 1977, Tardive dyskinesia: Are first signs reversible ? Am. J. Psychiatry 134: 84.PubMedGoogle Scholar
  23. Smith, J. M., and Baldessarini, R. J., 1980, Changes in prevalence, severity, and recovery in tardive dyskinesia with age, Arch. Gen. Psychiatry 37: 1368.PubMedCrossRefGoogle Scholar
  24. Smith, J. M., Burke, M. P., and Moon, C. O., 1981, Long-term changes in AIMS ratings and their relation to medication history, Psychopharmacol. Bull. 17: 120.PubMedGoogle Scholar
  25. Sovner, R. D., 1976, Dyskinesia associated with chronic antihistamine use, N. Engl. J. Med. 294: 113.Google Scholar
  26. Waddington, J. L., Youssef, H. A., Molloy, A. G., O’Boyle, K. M., and Pugh, M. T., 1985, Association of intellectual impairment, negative symptoms and aging with abnormal involuntary movements (“tardive” dyskinesia) in schizophrenia: Clinical and animal studies, J. Clin. Psychiatry 46 (4, Sec. 2): 24–33.Google Scholar
  27. Yagi, G., Ogita, K., Ohtsuka, N., Itoh, H., and Miura, S., 1976, Persistent dyskinesia after longterm treatment with neuroleptics in Japan, Keio J. Med. 25: 27.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1986

Authors and Affiliations

  • George Gardos
    • 1
  • Jonathan O. Cole
    • 2
  1. 1.West-Ros-Park Mental Health CenterBostonUSA
  2. 2.Psychopharmacology ServicesMcLean HospitalBelmontUSA

Personalised recommendations